Bibliography
- KALTHOFF FS, CHUNG J, STUETZ A: Pimecrolimus inhibits up-regulation of OX-40 and synthesis of inflammatory cytokines upon secondary T cell activation by allogeneic dendritic cells. Clin. Exp. Immunol (2002) 130(1):85–92.
- RAPPERSBERGER K, KOMAR M, EBELIN ME et al: Pimecrolimus identifies a common genomic anti-inflammatory profile, is clinically highly effective in psoriasis and is well tolerated. Invest. Dermatol (2002) 119(4):876–887.
- BENNETT BL, SATOH Y, LEWIS AJ: JNK: a new therapeutic target for diabetes. Carr: Opin. Phannacol (2003) 3(4):420–425.
- KORSTANJE C: Shifting attention from one cell type to another in dermatological research, but where are the new drugs? Carr: Opin. Investig. Drugs (2001) 2(5):624.
- HOUSTON P, GOODMAN J, LEWIS A et al.: Homing markers for atherosclerosis: applications for drug delivery, gene delivery and vascular imaging. FEBS Lett. (2001) 492(1-2):73–77.
- ASADULLAH K, STEERY W, STEPHANEK K et al: IL-10 is a key cytokine in psoriasis. Proof of principle by IL-10 therapy: a new therapeutic approach. Clin. Invest. (1998) 101(4):783–794.
- •This is the first paper to demonstrate the effects of rhuIL-10 in psoriasis.
- ASADULLAH K, DOECKE WD, EBELING M et al.: Interleuldn 10 treatment of psoriasis: clinical results of a Phase II trial. Arch. Dermatol (1999) 135(2):187–192.
- JUNG M, SABAT R, KRAETZSCHMARJ et al.: Expression profiling of IL-10-regulated genes in human monocytes and peripheral blood mononuclear cells from psoriatic patients during IL-10 therapy. Eur: Immunol (2004) 34(2):481–493.
- ••This paper describes the effects of IL-10 treatment on gene expression ex vivo.
- ECONOMIDES AN, CARPENTER LR, RUDGE JS et al.: Cytokine traps: multi-component, high-affinity blockers of cytokine action. Nat. Med. (2003) 9(1):47–52.
- DINARELLO CA: Setting the cytokine trap for autoimmunity. Nat. Med. (2003) 9(1):20–22.
- EDWARDS CK III, MARTIN SW, SEELY J et al.: Design of PEGylated soluble tumor necrosis factor receptor Type I (PEG sTNF-RI) for chronic inflammatory diseases. Adv. Drug Deify. Rev (2003) 55(10):1315–1336.
- PALLADINO MA, BAHJAT FR, THEODORAKIS EA et al: Anti-TNF-a therapies: the next generation. Nat. Rev Drug Discov. (2003) 2(9):736–746.
- LAM T, LING T, CHOWDHURY C et al: Synthesis of a novel family of diterpenes and their evaluation as anti-inflammatory agents. Bioorg. Med. Chem. Lett. (2003) 13(19):3217–3221.
- ONUFFERJ, MCCARRICK MA, DUNNING L et al.: Structure function differences in nonpeptide CCR1 antagonists for human and mouse CCR1.j. Immunol (2003) 170(4):1910–1916.
- BOZKURT B, TORRE-AMIONE G, WARREN MS et al.: Results of targeted anti-tumor necrosis factor therapy with etanercept (Enbrel) in patients with advanced heart failure. Circulation (2001) 103(8):1044–1047.
- SLIFMAN NR, GERSHON SK, LEE JH et al.: Listeria monocytogenes infection as a complication of treatment with tumor necrosis factor a-neutralizing agents. Arthritic Rheum. (2003) 48(2):319–324.
- •This paper describes infections observed in patients being treated with TNF blockers.
- LEE JH, SLIFMAN NR, GERSHON SK et al.: Life-threatening histoplasmosis complicating immunotherapy with tumor necrosis factor a antagonists infliximab and etanercept. Arthritis Rheum. (2002) 46(10):2565–2570.
- NETEA MG, RADSTASKE T, JOOSTEN LA et al.: Salmonella septicemia in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy. Arthritic Rheum. (2003) 48 (7):1853–1857.
- FRISHMAN JI, EDWARDS CK III, SONNENBERG MG, KOHNO T, COHEN AM, DINARELLO CA: Tumor necrosis factor (TNF)-a-induced interleukin-8 in human blood cultures discriminates neutralization by the p55 and p75 TNF soluble receptors. Infect. Dis. (2000) 182(6):1722–1730.
- ••Describes the effects of p75 and p55soluble TNF receptors in human whole blood.
- SCALLON B, CAI A, SOLOWSKI N et al:Binding and functional comparisons of two types of tumor necrosis factor antagonists. Pharmacol Exp. Ther. (2002) 301(2):418–426.
- VAN DEVENTER SJ: Transmembrane TNF-a, induction of apoptosis, and the efficacy of TNF-targeting therapies in Crohn's disease. Gastroenterology (2001) 121 (5):1242–1246.
- VAN DEN BRANDE JM, BRAAT H, VAN DEN BRINK GR et al.: Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease. Gastroenterology (2003) 124 (7):1774–1785.
- •Describes the mechanism of action of inflixirnab in Crohn's disease.
- BOUWMEESTER T, BAUCH A, RUFFNER H et al.: A physical and functional map of the human TNF-a/NF-icB signal transduction pathway. Nat. Cell Biol. (2004) 6(2):97–105.
Website
- http://www.FDA.gov.